Larimar Therapeutics, Inc. (LRMR)
NASDAQ: LRMR · Real-Time Price · USD
4.400
-0.040 (-0.90%)
At close: Apr 28, 2026, 4:00 PM EDT
4.490
+0.090 (2.05%)
After-hours: Apr 28, 2026, 7:31 PM EDT
Company Description
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform.
Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal disease.
The company is based in Bala Cynwyd, Pennsylvania.
Larimar Therapeutics, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 71 |
| CEO | Carole Ben-Maimon |
Contact Details
Address: Three Bala Plaza East, Suite 506 Bala Cynwyd, Pennsylvania 19004 United States | |
| Phone | 844 511 9056 |
| Website | larimartx.com |
Stock Details
| Ticker Symbol | LRMR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001374690 |
| CUSIP Number | 517125100 |
| ISIN Number | US5171251003 |
| Employer ID | 20-3857670 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Carole S. Ben-Maimon M.D. | Chief Executive Officer, President and Director |
| Michael Celano CPA | Secretary and Chief Financial Officer |
| Dr. Gopi Shankar M.B.A., Ph.D. | Chief Development Officer |
| John Berman | Vice President of Finance and Administration |
| Jennifer Spokes Johansson | Vice President of Legal and Compliance |
| Dr. Russell G. Clayton Sr., D.O. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 20, 2026 | ARS | Filing |
| Apr 20, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 10, 2026 | PRE 14A | Other preliminary proxy statements |
| Mar 19, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 19, 2026 | 10-K | Annual Report |
| Mar 19, 2026 | 8-K | Current Report |
| Mar 9, 2026 | 8-K | Current Report |
| Mar 2, 2026 | SCHEDULE 13D/A | Filing |
| Feb 27, 2026 | 8-K | Current Report |
| Feb 26, 2026 | 424B5 | Filing |